Compare
Aspire Biopharma Holdings, Inc. vs Alaunos Therapeutics, Inc. vs Genelux Corp vs Aditxt, Inc.
| Latest fiscal year | Aspire Biopharma Holdings, Inc. ASBP | Alaunos Therapeutics, Inc. TCRT | Genelux Corp GNLX | Aditxt, Inc. ADTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $6.2K | $5.0K | $8.0K | $3.2K |
| Revenue growth (YoY) | n/a | -50.0% | 0.0% | -97.6% |
| Gross margin | -1.9% | n/a | n/a | 8.4% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$24.48M | -$4.18M | -$32.15M | -$43.10M |
| EPS (Diluted) | -$16.38 | -$2.20 | -$0.86 | -$1153.83 |
| Operating cash flow | -$4.92M | -$2.87M | -$25.27M | -$25.69M |
| Free cash flow | n/a | -$2.97M | -$26.37M | -$25.70M |
| Cash & equivalents | n/a | $1.39M | $5.33M | n/a |
| Total assets | $1.31M | $2.97M | $19.03M | $16.52M |
| Total liabilities | $7.69M | $813.0K | $7.48M | $12.56M |
| Shareholders' equity | -$6.38M | $2.15M | $11.54M | $5.61M |
| Return on year-end equity | n/a | -194.0% | -278.5% | -768.3% |
| Shares outstanding | 3.53M | 2.35M | 38.14M | 411.5K |
Revenue, most recent five fiscal years
| Fiscal year | Aspire Biopharma Holdings, Inc. | Alaunos Therapeutics, Inc. | Genelux Corp | Aditxt, Inc. |
|---|---|---|---|---|
| Latest | $6.2K Ended 2025-12-31 | $5.0K Ended 2025-12-31 | $8.0K Ended 2025-12-31 | $3.2K Ended 2025-12-31 |
| 1 year earlier | n/a | $10.0K Ended 2024-12-31 | $8.0K Ended 2024-12-31 | $134.0K Ended 2024-12-31 |
| 2 years earlier | n/a | $5.0K Ended 2023-12-31 | $170.0K Ended 2023-12-31 | $645.2K Ended 2023-12-31 |
| 3 years earlier | n/a | $2.92M Ended 2022-12-31 | $11.07M Ended 2022-12-31 | $933.7K Ended 2022-12-31 |
| 4 years earlier | n/a | $398.0K Ended 2021-12-31 | n/a | $105.0K Ended 2021-12-31 |